ProPhase Labs, Inc. last reported quarterly results on Nov 19, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $883,000 (-37.6% year over year) and diluted EPS of -$0.16. It usually reports 44–50 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 19, 2025
50 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
-37.6%
|
-7
-3.8%
|
-0.16
+54.3%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
-17.1%
|
-4
+27.3%
|
-1.08
-227.3%
|
|
May 20, 2025
50 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1
-39.3%
|
4
+163.3%
|
1.13
+413.9%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
-83.1%
|
-7
-28.1%
|
-0.35
-16.7%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 9, 2024
39 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Mar 15, 2024
75 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
|
Nov 9, 2023
40 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRPH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 868278
- Former names
- QUIGLEY CORP (until May 18, 2010)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.